Valeant Pharmaceuticals International, Inc.

Form 4 July 30, 2013

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

OMB APPROVAL OMB

3235-0287 Number: January 31, Expires:

2005 Estimated average

0.5

burden hours per response...

Check this box if no longer subject to Section 16. Form 4 or Form 5

SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940

See Instruction 1(b).

par value

(Print or Type Responses)

1. Name and Addr Weldon Ryan	ess of Reporti	ng Person *	2. Issuer Name and Ticker or Trading Symbol	5. Relationship of Reporting Person(s) to Issuer			
			Valeant Pharmaceuticals International, Inc. [VRX]	(Check all applicable)			
(Last) 2150 ST. ELZE	(First)	(Middle) . WEST	3. Date of Earliest Transaction (Month/Day/Year) 07/26/2013	Director 10% Owner _X_ Officer (give title Other (specify below) EVP, Company Group Chairman			
	(Street)		4. If Amendment, Date Original Filed(Month/Day/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting			
LAVAL, A8 H7L 4A8 (City) (State) (Zin)				Person			

(City)	(State) (2	Table	I - Non-De	erivative S	Securi	ties Ac	quired, Disposed o	of, or Beneficial	ly Owned
1.Title of Security	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if	3. Transactio	4. Securi		or	5. Amount of Securities	6. Ownership Form: Direct	7. Nature of Indirect
(Instr. 3)	· · · · · · · · · · · · · · · · · · ·	any (Month/Day/Year)	Code Disposed of (D) (Instr. 8) (Instr. 3, 4 and 5)		1	Beneficially Owned	Beneficial Ownership		
		` '	,	I I		Following Reported	(Instr. 4)	(Instr. 4)	
					(A)		Transaction(s) (Instr. 3 and 4)		
Common			Code V	Amount	(D)	Price	,		
Stock, no par value	07/26/2013		M	5,173 (1)	A	\$0	68,611 <u>(2)</u>	D	
Common Stock, no	07/26/2013		F	2,683 (3)	D	\$ 0	65,928 <u>(2)</u>	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: Valeant Pharmaceuticals International, Inc. - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. Number one Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	of Derivative Expiration Date Gecurities (Month/Day/Year) Acquired A) or Disposed of D) Instr. 3, 4,		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. P Derr Seco (Ins
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Restricted Share Units	<u>(1)</u>	07/26/2013		M	5,173 (1)	<u>(1)</u>	(1)	Common Stock	5,173 (1)	

Reporting Owners

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

Weldon Ryan 2150 ST. ELZEAR BLVD. WEST LAVAL, A8 H7L 4A8

EVP, Company Group Chairman

Signatures

by: Nicholas Zanoni for Ryan Weldon

07/30/2013

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

4. The initial grant was reported to vest based on total shareholder return (TSR) between a price of \$26.51 starting on September 28, 2010 and the average stock price for the 20 trading days starting on each measurement dates: 25% on June 28, 2013, 50% on September 28, 2013 and 25% on December 28, 2013. Unit vesting is contingent on TSR performance between 15% and 45% into between one and three shares of common stock, respectively, with early vesting possible at higher TSR levels. The PSUs have already paid out for the first two of the three potential shares of common stock.

This represents the number of units vested on the performance-based RSUs ("PSUs") that were previously reported on the original Form

- (2) This number represents common shares purchased by the officer, common shares received upon settlement and/or exercise of previously granted equity awards, as well as other outstanding equity awards that were previously reported in Table 1.
- (3) This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Performance Share Units. Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2